At the news
? MIXEDIMPACT 7/10 8-K filed Mar 11, 2026 at 16:16 ET
Elutia reported its 2025 financial results, highlighted by the $88 million sale of its BioEnvelope business to Boston Scientific, which generated a net income of $53.4 million for the year. The company strengthened its balance sheet, repaid $26.9 million in debt, and now holds $44.4 million in cash and escrow. It also advanced its NXT-41x development program and initiated a strategic review of its SimpliDerm product line to focus on upcoming commercialization.
- Closed $88 million sale of BioEnvelope business to Boston Scientific in Q4 2025
- Full-year 2025 net income was $53.4 million (vs. $53.9 million net loss in 2024), driven by the gain on divestiture
- Full-year 2025 revenue from continuing operations declined 15.2% to $12.3 million (from $14.5 million)
- Company repaid $26.9 million in debt and ended 2025 with $36.4 million in cash and $8.0 million in escrow
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access